Interestingly, serum levels of the bile acids’ regulated FXR target gene FGF19 were significantly suppressed in CeD patients’ serum compared to controls, despite the majority of the CeD patients being in clinical remission (Figure 1F). This evidence concerns the gene FGF19 and cranioectodermal dysplasia.